✦ LIBER ✦

49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB)

✍ Scribed by T. Piratvisuth; G.K.K. Lau; P. Marcellin; W.C. Chow; G. Cooksley; M.W. Fried; S.W. Paik; Y.F. Liaw; M. Popescu; P. Button

Book ID: 117374331
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 131 KB
Volume: 44
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(06)80050-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

492 HBeAg and HBV DNA kinetics in HBeAg

492 HBeAg and HBV DNA kinetics in HBeAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB)

✍ M.W Fried; Y.E. Liaw; K.X. Luo; G.K.K. Lau; T. Piratvisuth; G. Cooksley; P. Marc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 124 KB

491 Peginterferon alpha-2a (40KD) (PEGAS

491 Peginterferon alpha-2a (40KD) (PEGASYS) reverses cirrhosis, improves fibrosis and slows progression of fibrosis in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B (CHB)

✍ G. Cooksley; G.K.K. Lau; P. Marcellin; T. Piratvisuth; E. Bonino; K.X. Luo; S. H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 251 KB

HBV DNA suppression in HBeAg-positive ch

HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo

✍ Bettina E. Hansen; Vincent Rijckborst; Martijn J. ter Borg; Prof. Harry L.A. Jan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 1 views

## Abstract The aim of the present study was to compare the decline of HBV DNA during peginterferon (PEG‐IFN) therapy with spontaneous HBV DNA decline in placebo‐treated patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B. A total of 136 patients who participated in a randomize

743 The majority of patients with HBeAg-

743 The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] sustain responses 2 years post-treatment

✍ P. Marcellin; E. Bonino; G.K.K. Lau; P. Farci; C. Yurdaydin; T. Piratvisuth; R. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 115 KB

P.112 Response is sustained two years po

P.112 Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®]

✍ P. Marcellin; F. Bonino; G.K.K. Lau; P. Farci; C. Yurdaydin; T. Piratvisuth; R. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 281 KB

484 On-treatment predictors of sustained

484 On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon α-2a (40 kDa) (PEGASYS®)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 135 KB